Historical background {#Sec1}
=====================

In higher organisms, blood and lymphatic vasculature is formed by two distinct processes: vasculogenesis and angiogenesis. Vasculogenesis is the de novo formation of vessels from hematopoietic precursor cells and predominantly takes place in the developing embryo. Angiogenesis, on the other hand, is the formation of vessels from preexisting vasculature by processes such as sprouting, pruning and intussusception \[[@CR1]\] and is an important biological process throughout the life of an organism, both under normal conditions and in disease. Impaired vessel function is the cause of many illnesses such as atherosclerosis, diabetic retinopathy, psoriasis, arthritis, malignant cell growth, neurodegenerative disease and a placental insufficiency, preeclampsia \[[@CR2]\]. Hematopoietic precursor cells are programmed by soluble factors, extracellular matrix (ECM) components as well as cell-cell contacts to mature to their final functional states during vessel formation. Research in this field has been profoundly stimulated by the discovery of a plethora of growth factors that instruct primordial cells to migrate, divide and differentiate and to give rise to endothelial cells that ultimately form blood and lymphatic vessels. Vascular endothelial growth factors, (VEGFs) are among the most important players that regulate vessel formation during embryonic development, in wound healing and in maintaining vessel homeostasis in adult organisms. In addition, impaired vessel function resulting from defects in VEGF ligands or receptors is the cause of many diseases. VEGF was originally described as vascular permeability factor (VPF), an activity released by tumor cells that promotes vascular leakage \[[@CR3]--[@CR12]\]. It is now clear that VPF represented a biological activity attributable to a family of polypeptide growth factors that are encoded by several genes. VEGFs specifically interact with hematopoietic cells, endothelial precursor cells, such as the angioblasts, and with differentiating and mature endothelial cells. The best studied variant is VEGF-A, which activates a plethora of signaling pathways through VEGF receptor-2 (VEGFR-2) and regulates vessel morphogenesis through VEGFR-1. The importance of VEGF-A and its receptors in vascular development has been best illustrated in knockout mice. Both VEGF-A \[[@CR13]\] and VEGFR-2 knockouts \[[@CR14], [@CR15]\] are lethal due to a deficiency in blood vessel formation, while VEGFR-1 knockouts show overgrowth of immature vessels that blocks the development of a fully developed functional vasculature and leads to embryonic death \[[@CR16]\]. The function of VEGFs in vessel formation is complemented by additional factors, such as basic fibroblast growth factor (bFGF) \[[@CR17]\], transforming growth factor β (TGFβ) \[[@CR18]\], platelet-derived growth factors (PDGFs) \[[@CR19]\] and angiopoietins \[[@CR20]\].

VEGF homologs also exist in arthropods, where they regulate hemocyte development upon binding to PDGF/VEGF receptors (PVRs). Apparently, in such simpler organisms, a single growth factor performs the tasks performed by PDGF and VEGF in higher organisms \[[@CR21]--[@CR23]\]. Apart from their role in vessel development and homeostasis, VEGF family proteins play diverse roles in other organs such as the neural system, bones, the hematopoietic system and the reproductive organs, which have been excellently reviewed recently \[[@CR24]\].

Biological function of VEGF receptors and their ligands {#Sec2}
=======================================================

VEGF family proteins {#Sec3}
--------------------

VEGF polypeptides belong to the PDGF family of growth factors. They are dimeric cysteine-linked secreted glycoproteins with an M~r~ of approximately 40 kDa. In mammals, VEGFs are encoded by a family of genes that includes VEGF-A, -B, -C, -D \[[@CR25]\] and PlGF \[[@CR26]\]. Highly related proteins called VEGF-E are encoded by pox viruses of the Orf family \[[@CR27]--[@CR29]\] and additional variants, collectively called VEGF-F, have been isolated from snake venoms \[[@CR30]--[@CR35]\]. Alternative splicing and proteolytic processing of VEGFs give rise to a number of functionally distinct isoforms with different signaling properties \[[@CR36], [@CR37]\]. For example, Bates and colleagues described an interesting variant, VEGF-A165b, closely related to VEGF-A165, that carries sequences encoded by exon 9, instead of exon 8, at the carboxy terminus \[[@CR38], [@CR39]\]. When added together with VEGF-A165 to endothelial cells, this variant inhibited VEGF signaling. The concept emerging from such studies is that multiple isoforms of VEGFs, binding their receptors with similar affinity, yet eliciting distinct signaling properties, are responsible for the bewildering complexity of VEGF-induced signal output.

VEGFs are expressed in response to hypoxia and when cells encounter specific growth and differentiation factors and are produced by many cell types, in particular by hematopoietic, stromal and endothelial cells \[[@CR40]--[@CR42]\]. One of the most prominent examples is the stimulation of VEGF expression by cancer cells that cannot form tumors bigger than a few millimeters unless they produce angiogenic growth factors \[[@CR2], [@CR43]\].

VEGF receptors {#Sec4}
--------------

The biological functions of VEGF polypeptides are mediated upon binding to type III receptor tyrosine kinases (RTKs), VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 (Flt-4) \[[@CR2], [@CR44]--[@CR47]\]. VEGF receptors are closely related to Fms, Kit and PDGF receptors. They consist of seven extracellular immunoglobulin (Ig)-like domains, a transmembrane (TM) domain, a regulatory juxtamembrane domain, an intracellular tyrosine kinase domain interrupted by a short peptide, the kinase insert domain, followed by a sequence carrying several tyrosine residues involved in recruiting downstream signaling molecules. These receptors are expressed on the cell surface of many bone-marrow-derived cells such as hematopoietic cells \[[@CR48]\], macrophages and endothelial cells \[[@CR49]\], on some malignant cells \[[@CR50]\] and on vascular smooth muscle cells (VSMCs) \[[@CR51]\]. Mutation analysis of the extracellular domains of VEGFR-1 and -2 showed that the second and third Ig-like domains constitute the high-affinity ligand-binding domain for VEGF with the first and fourth Ig domains apparently regulating ligand binding and receptor dimerization, respectively \[[@CR52]--[@CR54]\]. VEGFs show distinct patterns of receptor specificity as indicated in figure [1](#Fig1){ref-type="fig"}. VEGF-A binds to VEGFR-1 and -2 and to receptor heterodimers, while VEGF-C and -D bind VEGFR-2 and -3. Receptor-specific interactions have been described for some VEGF variants: PlGF \[[@CR55], [@CR56]\] and VEGF-B \[[@CR57]\] exclusively bind VEGFR-1 and VEGF-E interacts only with VEGFR-2 \[[@CR27], [@CR58]\]. VEGF-F variants interact with either VEGFR-1 or -2, e.g. VR-1 and Vammin bind only to VEGFR-2 \[[@CR32], [@CR33]\]. VEGF-A, -B and PlGF are predominantly required for blood vessel formation, while VEGF-C and -D are essential for the formation of lymphatic vessels \[[@CR59], [@CR60]\]. Figure 1Schematic representation of VEGF family ligands and their receptors.

Regulation of receptor activity {#Sec5}
-------------------------------

RTKs are activated upon ligand-mediated receptor dimerization \[[@CR61]--[@CR63]\]. Earlier published work suggested that ligand binding is not directly responsible for receptor dimerization but may induce conformational changes in the extracellular Ig domain 4 which then promote receptor dimerization \[[@CR64]--[@CR67]\]. Ligand-induced dimerization leads to structural changes transduced to the intracellular kinase domain upon rearrangement of the transmembrane and the juxtamembrane domain. The molecular mechanisms responsible for activation of the intracellular kinase domain of these receptors are poorly understood at present. Kit and PDGF receptors mutated in the trans- or juxtamembrane domains are constitutively active and often oncogenic \[[@CR68], [@CR69]\]. Similarly, a role of the TM domain in receptor activation has been elegantly documented for PDGF receptors carrying artificially engineered dimerization motifs \[[@CR70]\]. These data clearly establish that the TM and the juxtamembrane domains are involved in regulating receptor kinase activity.

All three VEGF receptors contain tyrosine phosphorylation sites that have an either regulatory or signaling function. While phosphorylation of sites in the juxtamembrane domain and the lower lobe of the kinase domain presumably modulates receptor structure and kinase activity, others act as docking sites for SH2-domain-containing signaling molecules. Four experimental approaches have been used to study the biological function of these phosphorylation sites: (i) mutation analysis in which specific tyrosine residues were mutated and receptor-associated signaling molecules and biological output were determined, (ii) phosphopeptide mapping of receptors isolated from resting and ligand-stimulated cells labeled with inorganic phosphate *in vivo*, (iii) phosphopeptide mapping of *in-vitro*-phosphorylated receptors, (iv) determination of the phosphorylation state of specific residues with phosphotyrosine-specific antibodies. Each of these methods has its shortcomings and published data on receptor activity and binding of downstream signaling molecules are therefore often difficult to compare. Mutational analysis, for example, might change receptor structure and therefore biological activity, while results from *in vivo* and *in vitro* phosphorylation analysis are biased by the different turnover of tyrosine phosphates labeled under these conditions.

VEGFR-1 regulates blood vessel morphogenesis {#Sec6}
--------------------------------------------

VEGFR-1 is an 180-kDa glycoprotein expressed in many hematopoietic cells. The receptor is required for normal blood vessel development during embryogenesis, since homozygous deletion of VEGFR-1 is lethal in mice at embryonic day E8.5 due to severe malformation of the vasculature \[[@CR16]\]. A VEGFR-1 splice variant lacking the intracellular tyrosine kinase and the transmembrane domain, sVEGFR-1 or sFlt-1, has been shown to be deficient in signaling, yet is expressed in many tissues during normal embryonic development. This molecule apparently acts as a decoy for VEGF ligands \[[@CR71]--[@CR73]\] and is clinically associated with a placental insufficiency, called preeclampsia, observed in some patients late in pregnancy \[[@CR74]\]. The view that VEGFR-1 kinase activity is dispensable for vessel development at particular developmental stages is further supported by the finding that a kinase-inactive VEGFR-1 mutant rescues VEGFR-1 null mutant mice \[[@CR75]\]. More recent data indicate that the kinase activity of VEGFR-1 plays an essential role during pathological angiogenesis and in wound healing, by potentiating VEGFR-2 signaling \[[@CR76]--[@CR78]\], however, the molecular details for this receptor cross-talk have not yet been elucidated. Undisputed is the role of kinase-active VEGFR-1 in recruiting hematopoietic cells from bone marrow precursors \[[@CR79], [@CR80]\].

VEGFR-1 has poor kinase activity compared with VEGFR-2 due to the presence of a repressor motif in the juxtamembrane domain, making studies on receptor phosphorylation difficult \[[@CR81]\]. A wide variety of signaling molecules has been shown to be activated by VEGFR-1 upon recruitment to specific phosphorylation sites \[[@CR82]--[@CR86]\]. Tyr1213 and 1333 serve as binding sites for adaptor molecules such as Nck, Crk, Grb-2 \[[@CR84], [@CR87]\], Sck \[[@CR88]\], the regulatory p85 subunit of phosphatidylinositol (PI) 3-kinase \[[@CR85]\] and the phosphatase SHP-2 \[[@CR87]\]. Phospholipase C*γ*-1 (PLC*γ*-1) has been shown to associate with VEGFR-1 via Tyr794 and 1169 \[[@CR86], [@CR89]\]. Tyr1242 and 1327 are minor phosphorylation sites with no interacting intermediates described to date. The downstream signaling pathways activated by VEGFR-1 are not well characterized and only weak proliferative or migratory effects are mediated by this receptor in endothelial cells. Conflicting reports indicate that VEGFR-1 has mitogenic potential in a PLC*γ*-1- and phosphokinase C (PKC)-dependent or independent manner \[[@CR89]--[@CR91]\]. Taking into account more recent results from P. Carmeliet's group, these data may arise from receptor cross-talk with VEGFR-2 \[[@CR76]\]. A single study shows activation of Fyn and Yes, two members of Src family kinases \[[@CR92]\], but no biological function has been attributed to these interactions. The function of VEGFR-1 is best established in monocyte migration and differentiation \[[@CR79], [@CR93]\], in the recruitment of endothelial cell progenitors from bone marrow \[[@CR80], [@CR94], [@CR95]\], the migration and invasion of carcinoma cells \[[@CR96]\] , the production of growth factors by liver sinusoidal endothelial cells \[[@CR97]\] and the adhesion of natural killer cells to endothelial cells \[[@CR98]\].

VEGFR-2 is the predominant receptor in angiogenic signaling {#Sec7}
-----------------------------------------------------------

VEGFR-2 is a 200-kDa glycoprotein expressed in hematopoietic \[[@CR48], [@CR99], [@CR100]\], neural \[[@CR101]--[@CR103]\] and retinal cells \[[@CR104]\]. VEGFR-2 regulates endothelial cell migration, proliferation, differentiation and survival as well as vessel permeability and dilation. Among the 19 tyrosine residues present in the intracellular domain of VEGFR-2, seven putative phosphorylation sites have been described in some detail to date: Tyr801, 951, 996, 1054, 1059, 1175 and 1214. A comprehensive study of receptor activity based on *in vitro* phosphorylation of immunoprecipitated VEGFR-2, on receptor mutagenesis and on *in vivo* mapping with phosphorylation site-specific antibodies identified Tyr951, 1054, 1059, 1175 and 1214 as the most prominent phosphorylation sites and Tyr1305, 1309 and 1319 as minor sites, while Tyr801 and 996 phosphorylation was not detected in this study \[[@CR105]\]. Tyr1175 is clearly the most important site implicated in activation of many pathways via PLC*γ*-1 \[[@CR106]\]. A role for Tyr1175 in endothelial and hematopoietic cell signaling was also shown in knockin mice expressing a Tyr1175 mutant. In this study, animals expressing the mutant receptor died in utero from vascular defects similar to those observed in VEGFR-2 null mice \[[@CR107]\]. A mutagenesis study led to the identification of Tyr1008 as an additional site involved in activation of PLC*γ*-1, promoting endothelial cell tubulogenesis and differentiation but not cell proliferation \[[@CR108]\].

The mechanism of receptor activation is not understood in molecular detail. Tyr1054 and 1059 in the kinase domain, which are homologous to regulatory residues present in all protein kinases, were tentatively identified as autophosphorylation sites \[[@CR109], [@CR110]\]. Similar to other RTKs, the putative phosphorylation sites Tyr801 and 822 located in the juxtamembrane domain may be phosphorylated following dimerization of VEGFR-2 and maintain the receptor in an active conformation \[[@CR111]\]. Mutation analysis also showed that Tyr996 and 1214 in the kinase and the carboxy-terminal domain are essential for receptor activation; however, one should bear in mind that such results may derive from structural changes in these mutant receptors \[[@CR109], [@CR112]\].

VEGFR-2 is downregulated and dephosphorylated upon internalization into endocytic vesicles \[[@CR109], [@CR113]\]. Both inactivation by directly associated phosphatases as well as dephosphorylation upon association with other membrane receptors carrying associated phosphatases such as SHP-1 and -2 have been described \[[@CR114], [@CR115]\]. A particularly interesting case is the downregulation of VEGFR-2 by tumor necrosis factor *α* (TNF*α*), which recruits SHP-1 to the plasma membrane \[[@CR116], [@CR117]\]. Finally, a variety of less well characterized signaling molecules have been shown to associate with the activated receptor and to transmit downstream signals. These include the Ras GT-Pase-activating protein GAP \[[@CR118]\], the adaptor proteins Nck \[[@CR118]\], Grb-2, Grb-10 and Sck \[[@CR88], [@CR114], [@CR119], [@CR120]\] and the human cellular protein tyrosine phosphatase A (HCTPA) \[[@CR121]\].

VEGFR-2 promotes mitogenesis {#Sec8}
----------------------------

VEGF-mediated endothelial cell proliferation depends on the activation of multiple pathways downstream from VEGFR-2. Similar to other members of the RTK family, VEGFR-2 activates the classical Ras-dependent signaling cascade impinging on MAP kinases such as ERK1 and 2 \[[@CR122]\]. In this pathway, VEGFR-2 recruits Grb-2, either by a direct interaction involving the putative docking site at Tyr1214 \[[@CR123]\], or via association with the adaptor protein Shc \[[@CR114]\]. Phosphorylation of Grb-2 leads to activation of the nucleotide exchange factor Sos followed by activation of Ras and stimulation of the Raf1/MEK/ERK signaling cascade. Cross-talk between ERK1 and 2 and another MAP kinase family member, c-Jun N-terminal protein kinase (JNK), has also been described, rendering difficult the assignment of specific biological roles to the individual MAP kinase family members \[[@CR124]\]. Activated MAP kinases translocate to the nucleus where they phosphorylate transcription factors and regulate gene expression.

Most studies on VEGF signaling agree that receptor recruitment of PLC*γ*-1 upon phosphorylation of Tyr1175 is essential for stimulation of mitogenesis. Activation of PLC*γ*-1 promotes phosphatidylinositol 4,5-bisphosphate (PIP~2~) hydrolysis giving rise to 1,2-diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP~3~). Production of DAG activates PKC resulting in Ras-independent Raf activation which leads to stimulation of ERK activity \[[@CR106], [@CR125]--[@CR128]\]. Treating cells with PKC inhibitors blocked mitogenic signaling by VEGF supporting a role for PKC in this pathway \[[@CR129]\]. Receptor association of PLC*γ*-1 via Tyr801 has been reported using receptor mutants \[[@CR86]\] and mutation analysis of VEGFR-2 showed that Tyr801 and 1175 are putative docking sites for the p85 subunit of PI 3-kinase \[[@CR130]\]. PI 3-kinase has also been implicated in mitogenic signaling by VEGFR-2, based on treatment of cells with specific inhibitors \[[@CR131]\]. This lipid kinase regulates the S6 kinase/Akt pathway which has been shown in many cell types to stimulate cell growth. Conflicting results suggest, however, that PI 3-kinase is not required for VEGFR-2-mediated mitogenesis \[[@CR122], [@CR126]\]. Taken together, these data, mostly based on mutagenesis studies, should be interpreted with some care since changes in receptor structure that alter association with signaling molecules may affect receptor readout.

Finally, c-Src and nitric oxide (NO) \[[@CR132]\] have been identified as intracellular mediators of VEGF signaling, and heparan sulfate and components of the ECM act as extracellular modulators in mitogenic signaling \[[@CR133], [@CR134]\], while the classical mechanism of 'contact inhibition of growth', described for epithelial cells or fibroblasts and mediated by VE-cadherin in endothelial cells, is reponsible for regulation of cell proliferation in a density-dependent manner \[[@CR135]\].

VEGFR-2 regulates cytoskeleton organization and cell migration {#Sec9}
--------------------------------------------------------------

The motogenic signals transduced by VEGFR-2 impinge on focal adhesion kinase (FAK), which regulates focal adhesion assembly and disassembly and actin organization. VEGF regulates FAK phosphorylation and activity and leads, together with paxillin and actin-anchoring proteins such as talin or vinculin, to recruitment of this kinase to focal adhesions \[[@CR136], [@CR137]\]. FAK activation has been shown to require signaling by PKC \[[@CR136]\]. In addition, Nck/PAK (p21-activated kinase) was shown to promote FAK phosphorylation and cell migration \[[@CR138]--[@CR141]\]. Src-dependent FAK phosphorylation was reported to regulate cell migration and survival \[[@CR142]\] and, consistent with these data, the Src kinase inhibitor M475271 blocked VEGF-induced endothelial cell migration \[[@CR143]\]. Besides its role in cellular proliferation, Tyr1175 phosphorylation has been shown to regulate stress fiber formation, focal adhesion assembly and cell migration upon recruitment of the adaptor protein Shb and subsequent activation of PI 3-kinase and FAK \[[@CR144]\]. More recently, Tyr951 located in the kinase insert domain and presumably phosphorylated by an associated kinase when VEGFR-2 is activated, was shown to recruit the adaptor molecule VRAP/TSAd (VEGF-receptor-associated protein/T-cell-specific adaptor molecule) in a subfraction of endothelial cells \[[@CR105]\]. This adapter molecule associates with Src, PI 3-kinase and PLC*γ*-1 and regulates actin organization and cell migration, but it also plays a crucial role in tumor angiogenesis \[[@CR105], [@CR145]\].

VEGF-induced endothelial cell migration is also mediated by stress activated protein kinase 2, SAPK/p38 \[[@CR139], [@CR146]\]. SAPK/p38 activity is regulated by Src and related focal adhesion protein kinase/proline-rich tyrosine kinase 2 (RAFTK/Pyk2) \[[@CR147]\]. Ca^2+^ mobilization and activation of Cdc42 have been shown to lead to SAPK/p38 phosphorylation \[[@CR147], [@CR148]\] and to induce phosphorylation of MAPKAP kinases 2 and 3 and the small heat shock protein HSP27 \[[@CR146], [@CR149]\]. This leads to the release of phosphorylated HSP27 from capped actin filaments, actin reorganization and the formation of stress fibers and lamellipodia which promote cell migration \[[@CR150]\]. Furthermore, a role for the small GTPases Rho and Rac, which modulate actin dynamics and cell contraction in endothelial cell migration and which are regulated by G proteins such as Gq/11 and Gbg and by PLC, is well documented \[[@CR151]\].

Signaling by VEGFR-2 is essential for cell survival {#Sec10}
---------------------------------------------------

VEGF also protects endothelial cells against apoptosis *in vitro* and *in vivo. In vivo*, the role of VEGF in preventing apoptosis is restricted to immature vessels that lack pericytes, as indicated by experiments showing that VEGF is essential for endothelial cell survival and blood vessel development in early postnatal life, but not in adult mice \[[@CR152]--[@CR154]\]. Activation of the PI 3-kinase/Akt pathway by VEGF protects cultured cells against apoptosis induced by serum starvation \[[@CR155], [@CR156]\]. Signal output from VEGFR-2 maintains adequate levels of active PI 3-kinase and thereby regulates the production of the second messenger phosphoinositide(3,4,5)trisphosphate (PIP~3~) which is required for activation of the serine/threonine kinase Akt \[[@CR157]\]. VEGF was also shown to induce the expression of anti-apoptotic molecules including the caspase inhibitors Bcl-2 and A1 \[[@CR158]\] and IAP (inhibitors of apoptosis) family proteins \[[@CR159]\]. Finally, survival signaling by VEGFR-2, PI 3-kinase and Akt depends on the integrity of adherens junctions that contain a transient tetrameric complex composed of VEGFR-2, PI 3-kinase, VE-cadherin and *β*-catenin \[[@CR160], [@CR161]\]. Disruption of this multimeric complex by loss or truncation of VE-cadherin induced endothelial cell apoptosis and blocked the transmission of PI 3-kinase-dependent survival signals.

VEGFR-2 regulates vessel permeability {#Sec11}
-------------------------------------

VEGF also regulates vascular permeability, and indeed was initially described as a vascular permeability factor \[[@CR3]\]. Increased vascular permeability is observed shortly after VEGF administration concomitant with the formation of so-called vesicular-vacuolar organelles, VVOs, \[[@CR162]\] and fenestrae \[[@CR163]--[@CR165]\]. These specialized regions in the plasma membrane of endothelial cells are highly permeable for macromolecules. How these membrane structures are formed is still unclear, but based on data from mutant mice lacking both c-Src and c-Yes, which showed reduced vascular permeability after VEGF administration, a role for Src family kinases has been suggested \[[@CR166]\]. Addition of VEGF to endothelial cells induces expression of the plasmalemmal vesicule-associated protein (PLVAP), a component of diaphragmed endothelial fenestrations. PLVAP expression is regulated by PI 3-kinase and SAPK/p38 \[[@CR167]\]. In mature vessels, VEGF also regulates vascular permeability by loosening the junctions between endothelial cells, giving rise to the formation of transcellular gaps. Phosphorylation of major components of tight, adherens and gap junctions, such as VE-cadherin \[[@CR168]--[@CR170]\], *β*-catenin \[[@CR168], [@CR171]\], occludin and zonula occluden 1 \[[@CR172], [@CR173]\] and of connexin 43 \[[@CR174]\] have been reported in response to VEGF. Vessel dilation and permeability are also regulated by NO which is upregulated by Akt upon induction of endothelial NO synthase (eNOS) expression \[[@CR175], [@CR176]\]. Blocking eNOS and cyclooxygenase with specific inhibitors prevents the release of NO and prostacyclin (PGI2) and blocks VEGF-induced vessel hyperpermeability \[[@CR177]\].

VEGFR-3 regulates lymphangiogenesis {#Sec12}
-----------------------------------

VEGFR-3 is synthesized as a 195-kDa precursor protein consisting of seven extracellular Ig-like domains, a TM and an intracellular kinase domain. The protein is proteolytically processed in the fifth Ig domain giving rise to a 125- and a 75-kDa chain held together by a disulfide bond \[[@CR178], [@CR179]\]. Expression of this receptor starts at E8.5 of mouse development in all embryonic endothelial cells. After E8.5, VEGFR-3 expression is only seen on developing veins and lymphatics but not on arteries \[[@CR59], [@CR180]\]. Later in development, the expression gradually becomes restricted to lymphatic vessels. In VEGFR-3 null mice, vascular remodeling and maturation are abnormal in larger vessels with a defective lumens causing fluid accumulation in the pericardial cavity and embryonic death at E9.5 \[[@CR181]\]. Recent reports also showed expression of the receptor on blood vessels in the vicinity of tumors as well as on several benign and malignant tumor cells \[[@CR182], [@CR183]\]. A role for VEGFR-3 in cell-to-cell signaling in adult blood vessel angiogenesis, where the expression of this receptor and its ligands seems to be induced by VEGF-A, has also been suggested \[[@CR184]\]. VEGFR-3 is activated by VEGF-C and -D, and proteolytic processing of these ligands gives rise to variants also interacting with VEGFR-2, although with lower affinity than with VEGFR-3. VEGFR-3 apparently also heterodimerizes with VEGFR-2 in lymphatic endothelial cells, expanding the repertoire of signaling pathways activated by this receptor \[[@CR185]\]. Paracrine expression of VEGF-C at sites of lymphatic sprouting further supports a role for VEGFR-3 in the development of lymphatic vessels \[[@CR186]\]. VEGFR-3 promotes cell migration and survival in lymphatic endothelia by inducing PKC-dependent MAP kinase activation and via a wortmannin-sensitive pathway requiring PI 3-kinase and Akt \[[@CR187], [@CR188]\]. In addition, a splice variant of this receptor has been shown to bind SHC \[[@CR189]\]. That signaling via VEGFR-3 is a prerequisite for lymphangiogenesis is further supported by data showing that a soluble, kinase-deficient receptor variant blocks lymphatic vessel formation \[[@CR190], [@CR191]\].

VEGF receptors form multiprotein complexes with various coreceptors {#Sec13}
===================================================================

VEGF signaling is complicated by the fact that the ligands and their receptors interact with additional cellular proteins such as neuropilins, heparan sulfate, integrins and cadherins. These interactions allow coordination of signal strength, timing and specificity with extracellular cues arising from soluble ligands, cell-cell and cell-substratum interactions.

Association with heparan sulfate and neuropilins {#Sec14}
------------------------------------------------

The short form of VEGF-A, VEGF-A121, encoded by exons 2--5 and 8, consists of a receptor-binding domain specific for VEGFR-1 and -2 and is a poor mitogen. The longer VEGF-A165 isoform, that also contains sequences encoded by exon 7, binds the receptors with similar affinity as VEGF-A121 but displays increased signaling potential \[[@CR192]--[@CR194]\]; the underlying mechanism remains unclear at present. All isoforms carrying exon 7, or 6 plus 7, such as VEGF-A165, VEGF-A183, VEGF-A189 and VEGF-A203, interact with proteins of the neuropilin family and with heparan sulfate \[[@CR193]--[@CR202]\]. Neuropilin-1 and -2 interact with VEGFR-2 and -1, respectively, stimulating signaling by these receptors. Interaction of VEGF-A165 with neuropilin-1 is particularly important for endothelial tip cell guidance where regulation of cell migration is the predominant signal output \[[@CR203], [@CR204]\]. VEGF-A165 has also been shown to interact with neuropilin-1 and VEGFR-2 expressed separately on adjacent cells. This may be particularly important during endothelial cell guidance when vessels are formed along tracks predetermined by neural cells \[[@CR205]--[@CR207]\].

Association with integrins {#Sec15}
--------------------------

Integrins play an important role in cell signaling linking intracellular signaling pathways activated by soluble factors to output elicited by cellular interactions with the ECM and with neighboring cells. Specific integrins bind to the extracellular domain of VEGFR-2 and augment receptor signaling \[[@CR208]\]. Integrins of the *β*~3~ subfamily specifically bind to the extracellular domain of VEGFR-2 resulting in increased receptor activation upon VEGF stimulation \[[@CR209]--[@CR211]\]. Direct interaction between *β*~3~ integrin and VEGFR-2 is restricted to *α*~v~*β*~3~ and was shown to be either ligand independent \[[@CR210]\] or dependent \[[@CR211]\]. VEGFR-2 signaling in the context of *α*~1~*β*~1~ and *α*~2~*β*~1~ integrins has been shown to regulate lymphangiogenesis during tissue repair, further demonstrating how output from VEGF receptors is modulated by cellular interactions with the ECM \[[@CR212]\]. VEGFR-2-mediated angiogenesis is also directly regulated by integrins as proposed by work performed in knockout mice lacking *β*~3~ or *β*~5~ integrin \[[@CR213], [@CR214]\]. Animals that did not express these integrins showed increased VEGFR-2 activity and tumor vascularization. Taken together these studies suggest that integrins act as 'gatekeepers', preventing aberrant stimulation of resting endothelial cells under non-pathological conditions, or as 'caretakers', which facilitate angiogenesis during vessel repair in disease \[[@CR215]\].

VEGF bound to the ECM promotes integrin-dependent cell spreading, migration and survival that do not require signaling by VEGF receptors \[[@CR216]\]. Similarly, sVEGFR-1 interacts with *α*~5~*β*~1~ integrin thus becoming part of the ECM and promoting cell migration and spreading \[[@CR217]\]. In addition, interaction of VEGF-A with fibronectin, an ECM component interacting predominantly with *α*~5~*β*~1~ and, to a minor extent, with the vitronectin receptor *α*~v~*β*~3~, has been reported recently \[[@CR218]\]. Finally, in cells grown on fibronectin instead of vitronectin or collagen, increased biological activity of VEGF and augmented endothelial cell migration and MAP kinase activity were reported \[[@CR219]--[@CR221]\].

Association with cadherins {#Sec16}
--------------------------

Cadherins are involved in the formation of adherens junctions in endothelial and epithelial cells and play an essential role in VEGF signaling \[[@CR160], [@CR222]--[@CR225]\]. Interaction of VEGFR-2 with VE-cadherin is regulated by *β*-catenin. At high cell density, the phosphatase PTP1/Dep1/CD148 associates with VE-cadherin and attenuates tyrosine phosphorylation of VEGFR-2 thereby suppressing signaling via PI 3-kinase, MAP kinases and PLC*γ*-1 \[[@CR135]\]. At low cell density, such as at the tip of developing blood vessels, VEGFR-2 associates with integrin *α*~v~*β*~3~ instead of cadherin and signal output is directed toward stimulation of cell migration and mitogenesis \[[@CR215]\]. Reduced turnover of VEGFR-2 at high cell density has also been demonstrated to depend on cadherin and to enhance VEGF-mediated activation of MAP kinases \[[@CR226]\]. To a large extent, vessel homeostasis is determined by cell-to-cell junctions that play an essential role during formation of a mechanosensory complex that regulates the response of endothelial cells to fluid shear stress \[[@CR227]\].

Structure of VEGF receptors and their ligands {#Sec17}
=============================================

The structures of VEGF-A \[[@CR228], [@CR229]\], PlGF \[[@CR230]\] and the snake venom components Vammin and VR-1 \[[@CR31]\] have been solved. These molecules form homodimers and fold into a cysteine-knot structure also described for other growth factors \[[@CR231]\]. The structure of Ig domain 2, which is part of the ligand-binding domain of VEGFR-1, has also been determined \[[@CR232]\] and there are structural data available for complexes formed between VEGF-A and PlGF with domain 2 of VEGFR-1 \[[@CR233]--[@CR235]\]. These structural studies were complemented with biochemical investigation of receptor-blocking peptides \[[@CR236], [@CR237]\]. Biochemical analysis also led to the identification of specific residues determining receptor selectivity \[[@CR56], [@CR229], [@CR238], [@CR239]\].

The extracellular Ig-like domain 2 is sufficient for high-affinity binding of VEGF-A to VEGFR-1, while domains 2 and 3 are required for binding to VEGFR-2 \[[@CR54]\]. VEGF mutants with altered loops L1 and L3 were used to determine the molecular basis for receptor selectivity of VEGF polypeptides \[[@CR239], [@CR240]\]. We created similar chimeric molecules based on our recently solved structure of the VEGFR-2-specific VEGF-E NZ2 variant. Loops L1 and L3 are tightly associated at their base and apparently function as a structural entity determining receptor selectivity, while L2 is required for interaction with both receptors \[unpublished data\].

The structure of the heparan-sulfate- and neuropilin-1-binding domain of VEGF-A, encoded by exons 7 and 8, has been solved by nuclear magnetic resonance spectroscopy \[[@CR241]\]. Analysis of the electrostatic surface potential shows an extended patch of positively charged residues on one side of the molecule that is a candidate binding site for negatively charged heparan sulfate side chains. All VEGFs carrying sequences encoded by exon 7 bind to heparan sulfate both *in vitro* and *in vivo* \[[@CR242]\]. However, high-affinity interaction with heparan sulfate, and particularly with neuropilin-1, also requires the short carboxy-terminal peptide encoded by exon 8 as shown by our laboratory \[unpublished data\].

Clearly, additional in-depth structural information is required for a comprehensive understanding of VEGF interaction with VEGFR-1 and -2, neuropilin-1 and heparan sulfate. Similarly challenging is the task to unravel the structural changes in the intracellular kinase domain following ligand binding to the extracellular domain. A first step in this direction is the resolution of a partial structure of the kinase domain of VEGFR-2 \[[@CR243]\]. Such information will be useful to dissect the activation mechanism of VEGF receptor kinases and to engineer more specific reagents interfering with receptor activation, with the goal to block or stimulate VEGF signaling in disease.

Conclusions {#Sec18}
===========

Endothelial cells integrate signals elicited by cell-cell contacts, cell-extracellular matrix interactions and angiogenic growth factors. The final signal output results from the formation of context-specific signaling modules in distinct membrane compartments where receptor activity is tuned to the specific needs of a particular cell and aberrant signaling is suppressed \[[@CR244]\]. Signal specificity of VEGF receptors arises from combinatorial activation of multiple cellular pathways. Each receptor subtype assembles a distinct set of signaling molecules in a spatially and temporally controlled manner giving rise to the formation of specific signal transduction modules or 'signalosomes' at the plasma membrane. *In vivo*, cells release VEGFs into their neighborhood in a temporally and spatially well-defined manner that allows gradual formation of receptor-ligand complexes. This significantly differs from tissue culture models where growth factors are usually administered as a single bolus, and great caution is required when extrapolating such *in vitro* data to the *in vivo* situation. Signal output is also determined by competition among the various VEGF receptors for VEGFs that interact with more than one receptor isoform and is influenced by the kinetics with which receptors are activated by different ligands. Finally, the exact three-dimensional structure of each ligand-receptor-coreceptor complex determines the efficacy with which intracellular tyrosine residues are phosphorylated and subsequently exposed to downstream signaling molecules. This has an impact on the strength and the kinetics with which individual signaling pathways are activated and execute their tasks.
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